Increasing prevalence of genetic diseases such as Down syndrome, Edward syndrome, and Patau syndrome in newborn and prenatal is the high impact rendering driver for the growth of prenatal & newborn genetic testing market. Increasing demand for prenatal & newborn genetic testing for identifying genetic abnormalities and determining the sex of fetus before 8 to 11 months gestation are the driving factors for the growth of this market. Some other drivers for prenatal & newborn genetic testing market include increasing R&D activities related to genomics and proteomics, extensive presence of public and private-public organizations such as the National Human Genome Research Institute (NHGRI) and Genomic Health Inc. and advancement in technology. Increasing approaches for novel diagnostic techniques and tools and emerging genome profiling technologies such as TaqMan PCR are expected to grow this market at the rapid pace.
On the basis of technology, prenatal & newborn genetic testing market is segmented into diagnostics methods and screening techniques. Diagnostics methods are classified into PCR (polymerase chain reaction), aCGH (array-comparative genetic hybridization), and (FISH (fluorescence in-situ hybridization). However, screening techniques are segmented into non-invasive prenatal tests includes Verifi, Harmony, MaterniT21 Plus, Panorama, PrenaTest, NIFTY, and Bambni Test) and MMS (maternal serum screening). Polymerase chain reaction is a technique in which a single piece or a few copies of DNA are used to amplify millions of copies of a particular sequence of DNA. It is the most common and indispensable technique used in biological and medical research laboratories for a wide range of applications such as DNA-based phylogeny, genetic fingerprints identification, diagnosis of hereditary diseases, and functional analysis of genes.
The global prenatal and newborn genetic testing is segmented into four major regions such as Europe, North America, Asia Pacific, and RoW. The North American market is considered as most dominant market due to favorable government policies towards proper diagnosis and screening of genetic abnormalities and the presence of advanced technologies such as multiplex PCR technologies and real time PCR equipment. The Asia Pacific market is expected to show lucrative growth during the forecast period owing to the development of various plans and policies of government, improvements in healthcare services, rising awareness of genetic disease diagnosis, and rising economic development. Key players in this market include Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina, Inc., and Natera Inc.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.